Though ovarian cancer ranks seventh in the list of the most common types of cancers worldwide, its affliction rate continues to rise.
These are the estimates of the World Cancer Research Fund International, which also states that the prevalence of this disease remarkably higher in less developed countries.

Browse the full Asia Pacific Ovarian Cancer Market Report : http://www.mrrse.com/ovarian-cancer-therapeutics

Within Asia Pacific, countries where ovarian cancer pipelines are most active are: China, India, Japan and Australia. Even as this market continues to thrive and grow at a steady pace, a recent market report by MRRSE carries some interesting trends. These are:
• The Asia Pacific ovarian cancer therapies market features a white space for maintenance therapies. At present, the most widely used type of chemotherapy is the platinum-based one.
The use of paclitaxel and carboplatin chemotherapy regimen is seen to be the most commonly-used one. Data shows that this is the most widely used standard of care for treating platinum-sensitive ovarian cancer in both first-line as well as recurrent cases.
• The prognosis for platinum-resistant ovarian cancer is currently poor, and leaves a wide gap where companies can fill with innovative solutions.
Thus, the demand for maintenance therapies is high in the Asia Pacific ovarian cancer market. Moreover, the time is right for
market players to invest in developing more effective treatment solutions for patients that are afflicted with platinum-sensitive ovarian cancer.
• Approvals for olaparib and trebananib, two promising drug candidates for the treatment of ovarian cancer, are expected to come through before 2020.
But even after being approved, their penetration rates will remain somewhat restricted to the surface of the ovarian cancer market. Currently, the ovarian cancer therapeutics pipeline is rather crowded, but it still leaves a lot to be desired on the efficacy of late-stage drugs. Only minimal improvements have been observed in progression-free survival rates.

Browse the full Press Release of Ovarian Cancer Market : http://www.mrrse.com/ovarian-cancer-therapeutics-market-report

Based on the factors discussed above, it can be said that the ovarian cancer market in Asia Pacific will not be driven by new drug approvals.
Growth will primarily be a result of inflation and the general rise in the prevalence rates of ovarian cancer. On the positive side, the large number of drug candidates in the ovarian cancer pipeline will keep the industry’s interest levels and degree of competition moderately high.

Send An Enquiry: http://www.mrrse.com/enquiry/112

Table of Contents:
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Pathophysiology
2.1.1 Ovarian Cancer – A Group of Distinct Diseases
2.1.2 Ovarian Cancer is Highly Heterogenic with Multiple Mutations and Affected Signaling Pathways
2.2 Symptoms and Diagnosis
2.3 Risk Factors
2.3.1 Age
2.3.2 Inherited Genetic Mutations
2.3.3 Greater Number of Lifetime Ovulations
2.3.4 Weight
2.3.5 Previous Medical Conditions
2.4 Treatment Algorithm
2.4.1 Surgery
2.4.2 First-Line Chemotherapy
2.4.3 Maintenance Therapy
2.5 Recurrent Disease

3 Marketed Products
3.1 Carboplatin
3.2 Paclitaxel
3.3 Gemcitabine
3.4 Topotecan
3.5 Pegylated Liposomal Doxorubicin
3.6 Yondelis
3.7 Avastin
4 Product Pipeline
4.1 Overview of Pipeline by Phase and Route of Administration
4.2 Overview of Pipeline by Molecule Type, Mechanism of Action and Molecular Target
4.2.1 Molecular Targets in the Developmental Pipeline
4.3 Clinical Trials
4.3.1 Clinical Trial Duration
4.3.2 Clinical Trial Size
4.3.3 Failure Rate
4.3.4 Discussion
4.4 Late-Stage Drugs in Developmental Pipeline
4.4.1 Niraparib
4.4.2 Olaparib
4.4.3 Vargatef
4.4.4 Trebananib
4.4.5 Farletuzumab
4.4.6 Karenitecin
4.5 Discussion

Contact
State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States
Telephone: +1-518-618-1030
Email: [email protected]
Website: http://www.mrrse.com/